Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, has announced a strategic partnership with Anthropic to deploy Claude, an advanced AI platform, across its operations. This initiative aims to enhance the discovery, development, and delivery of transformative medicines by integrating AI capabilities into daily workflows. The deployment will empower more than 30,000 employees and focus on three key areas: engineering, drug development, and manufacturing. In engineering, BMS will utilize Claude Code to streamline software and AI development, unlocking valuable data trapped in existing systems. For drug development, Claude will automate trial documentation processes, potentially reducing the time from data lock to regulatory filing. Additionally, in manufacturing, Claude will facilitate quality assurance and compliance, expediting product delivery to patients. This collaboration builds on BMS's previous investments in AI, reinforcing its position as a leader in the biopharmaceutical sector. Greg Meyers, BMS's Chief Digital & Technology Officer, stated that leveraging AI is crucial for accelerating innovation and improving patient outcomes. The integration of Claude represents a significant step toward transforming how BMS operates in the competitive biopharma landscape.